Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.56 |
| ▸ | PNMT | P11086 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942082 | 0.82 | CD44 (0.56) | CD44PNMTMAOBPRCPHTR2C | |
| Hydrochloric Acid SCHEMBL5609302 | 0.81 | CD44 (0.47) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL14012985 | 0.79 | CD44 (0.53) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL27840574 | 0.79 | CD44 (0.49) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL19326980 | 0.78 | CD44 (0.51) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL27840578 | 0.78 | CD44 (0.51) | CD44PNMTMAOBPRCPHTR2C | |
| Hydrochloric Acid SCHEMBL5777132 | 0.77 | CD44 (0.50) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL27840576 | 0.77 | CD44 (0.50) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL27840575 | 0.77 | CD44 (0.46) | CD44PNMTMAOBPRCPHTR2C | |
| SCHEMBL23798393 | 0.76 | CD44 (0.49) | CD44PNMTMAOBPRCPHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680137-B1 | Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication | HOFFMANN LA ROCHE (CH) | 2012-11-21 | — | — | EP | disclosed |
| EP-2407470-A2 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | F. Hoffmann-La Roche Ltd. (CH) | 2012-01-18 | — | — | EP | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CD44 4883/4885PNMT 2339/4885MAOB 1174/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CD44 4883/4885PNMT 2339/4885MAOB 1174/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CD44 4883/4885PNMT 2339/4885MAOB 1174/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | CD44 4883/4885PNMT 2339/4885MAOB 1174/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CD44 4883/4885PNMT 2339/4885MAOB 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.